Doctor Reveals The Fat Burning Peptide That No One is Talking About (AOD-9604)
A telemedicine clinic founder argues AOD-9604 works as a fat mobilizer only when paired with a calorie deficit, and covers its trial history, pairing, sourcing and fasting.
Key moments
Tap a moment to play the video from there.
- 1:13What AOD-9604 isJones describes it as a synthesized version of a fat-metabolism region of human growth hormone and says it is related to, but not identical to, HGH frag.
- 2:32Mobilizer, not appetite suppressantHe says AOD-9604 releases stored triglycerides as free fatty acids but does not suppress appetite or burn calories at rest.
- 3:33Six trials and safety dataHe says 925 people took part in six trials from 2001 to 2007, with side effects he describes as matching placebo.
- 4:35Why the developer stoppedAccording to Jones, the company ended development in 2007 because the peptide alone gave unimpressive weight loss, and he argues it was tested without a calorie deficit.
- 6:00Demand and supply frameworkHe lays out a calorie deficit as system one and fat mobilization as system two, and argues long-term deficits without fat access stress the body.
- 8:28FDA category two listHe says the FDA listed AOD-9604 as a possible significant safety risk, then nominations were withdrawn in late 2024 and it went into review.
- 10:14Pairing with GLP-1 and fastingJones says a GLP-1 should come first, then AOD-9604, with fasting added. He says stalled patients in his clinic move within weeks.
- 13:01Research grade sourcing risksHe says research grade means no guarantee of purity or sterility, and suggests vendor research, certificates of analysis and independent testing.
- 16:52Building metabolic flexibilityHe says three to four months of pairing with fasting trains the body to burn stored fat, with the goal of using AOD-9604 only situationally.
What the video says
Dr. Jones, a chiropractor who runs a telemedicine clinic, presents AOD-9604 as an underused peptide. He describes it as a modified fragment of human growth hormone, based on amino acids 176 through 191, and says it is sometimes called HGH frag, though he notes the two are not identical. His central claim is that it is a fat mobilizer, not an appetite suppressant or a stimulant, so it releases stored fat but does not itself create a calorie deficit.
He says six trials between 2001 and 2007 enrolled 925 people and showed side effects indistinguishable from placebo, with no rise in IGF-1, no blood sugar problems and no serious adverse events. According to him, the developer stopped in 2007 because the peptide alone did not produce dramatic weight loss, which he compares to judging a key without a door. He also says the FDA placed it on its category two list, nominations were withdrawn in late 2024, and it moved into review.
The second half is about use. Jones describes a two-part framework: a calorie deficit first, usually from a GLP-1 drug such as semaglutide, tirzepatide or retatrutide, then AOD-9604 added to give access to stored fat. He says that with a GLP-1 and fasting, stalled patients in his clinic see movement within weeks, and that fasting feels smoother. He says it is aimed at people with insulin resistance, PCOS or menopause-related issues.
He also discusses sourcing, saying research grade products carry no purity or sterility guarantee, and recommends vendor checks, certificates of analysis and independent testing. He says patients improved after switching to pharmacy grade product from a 503A pharmacy. He closes with metabolic flexibility over three to four months. Much of the video promotes his clinic's discovery calls, and the claims are his clinical observations.
On each compound
AOD-96041:13
Jones describes it as a modified fragment of human growth hormone that mobilizes stored fat, and says it needs a calorie deficit to work. He says it was safe in six trials with 925 people and that he uses it with patients and himself.
See how your DNA reads AOD-9604Semaglutide10:45
Jones names it, with tirzepatide and retatrutide, as a typical way to create the calorie deficit before adding AOD-9604.
See how your DNA reads SemaglutideTirzepatide10:45
Jones lists it among GLP-1 medications he says most people would use as the first step, before adding AOD-9604.
See how your DNA reads TirzepatideRetatrutide10:45
Jones lists it among GLP-1 medications he says most people would use as the first step, before adding AOD-9604.
See how your DNA reads RetatrutideWhat this video doesn’t settle
- The efficacy claims come from the speaker's own clinic experience, with no control group or published data shown.
- He does not cite the trial results on weight loss, so the claim that the trials failed only for lack of a calorie deficit is his interpretation.
- The video does not give dosing, timing or protocol details, which he offers to cover in a future video.
Questions this video answers
What does Dr. Jones say AOD-9604 does?
He says it is a fat mobilizer that releases stored triglycerides as free fatty acids so the body can use them for energy. He says it is not an appetite suppressant or a stimulant, and does not itself burn what it releases.
Why does Dr. Jones say AOD-9604 failed in clinical trials?
He says the developer stopped in 2007 because the peptide alone did not produce dramatic weight loss. His argument is that it was tested without a calorie deficit, so it had nothing to act on.
What does Dr. Jones say about the safety of AOD-9604?
He says six trials with 925 people showed side effects indistinguishable from placebo, with no IGF-1 increase, blood sugar problems or serious adverse events. He also says the FDA put it on its category two list, which was later withdrawn in late 2024 and moved to review.
How does Dr. Jones recommend sourcing AOD-9604?
He says research grade products are made for lab use and carry no purity or sterility guarantee. He suggests checking vendors, looking for third-party certificates of analysis and testing a sample independently, and says patients did better on pharmacy grade product from a 503A pharmacy.
Video by Dr. Jones, DC on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
